CervoMed Inc. (CRVO) Financial Analysis & Valuation | Quarter Chart
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer&#... more
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercializat... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $22.50M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | John J. Alam |
| IPO Date | 2008-05-23 | CAGR | -3.97% |
| Employees | 15 | Website | www.cervomed.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
CRVO chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $5.22M | P/E | -0.74 | Forward P/E | -1.65 | PEG | — |
| P/S | 6.71 | P/B | 0.1 | P/CF | -0.09 | P/FCF | -0.07 |
| Sales | $322,569 | Sales 1Y | inf% | Sales 3Y | inf% | Sales 5Y | inf% |
| EPS | $-3.28 | EPS 1Y | 24.42% | EPS 3Y | -65.33% | EPS 5Y | -81.06% |
| Sales QoQ | — | EPS QoQ | -25.58% | Sales QoQ Avg | — | EPS QoQ Avg | -0.79% |
| Gross Margin | 100% | Operating Margin | -9661.43% | Profit Margin | -9408.76% | ROCE | -123.15% |
| ROA | -117% | ROE | -156% | Altman Z Score | -4.28 | Piotroski Score | 3 |
| Current Ratio | 37.83 | Quick Ratio | 37.83 | Cash Ratio | 32.69 | Op. CF Ratio | -10.07 |
| Debt/Equity | — | Debt/Assets | — | Lt Debt/Equity | — | Lt Debt/Cap. | — |
| Intrst Cov. | — | Inventory Turnover | — | Asset Turnover | 0.01 | Receivables Turnover | — |
| Enterprise Value | $5.22M | P/E Ratio | -0.74 |
| Forward P/E | -1.65 | PEG Ratio | — |
| P/S Ratio | 6.71 | P/B Ratio | 0.1 |
| P/CF Ratio | -0.09 | P/FCF Ratio | -0.07 |
| EPS | $-3.28 | EPS Growth 1Y | 24.42% |
| EPS Growth 3Y | -65.33% | EPS Growth 5Y | -81.06% |
| Revenue Growth 1Y | inf% | Gross Margin | 100% |
| Operating Margin | -9661.43% | Profit Margin | -9408.76% |
| ROE | -156% | ROA | -117% |
| ROCE | -123.15% | Current Ratio | 37.83 |
| Quick Ratio | 37.83 | Cash Ratio | 32.69 |
| Debt/Equity | — | Interest Coverage | — |
| Altman Z Score | -4.28 | Piotroski Score | 3 |
CervoMed Inc. (CRVO) valuation & financials
CervoMed Inc. (CRVO) has a market capitalization of $22.50M and trades at a price-to-earnings ratio of -0.7. It operates in the Healthcare sector (Biotechnology).
CervoMed Inc.'s revenue grew — over the last year.
CervoMed Inc.'s next earnings report is scheduled for November 12, 2026 after market close (provider scheduled date); analysts estimate EPS of $-0.61. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)